Portal de Periódicos da CAPES

Multiple Sclerosis and Related Disorders

2016; European Bioinformatics Institute; Volume: 6; Linguagem: Inglês

Jamie McDonald, Jennifer Graves, Amy Waldman, Timothy Lotze, Teri Schreiner, Anita Belman, Benjamin Greenberg, Bianca Weinstock‐Guttman, Gregory Aaen, Jan‐Mendelt Tillema, Janace Hart, Sabeen Lulu, Jayne Ness, Yolanda Harris, Jennifer Rubin, Meghan Candee, Lauren Krupp, Mark Gorman, Lina Benson, Moses Rodriguez, Tanuja Chitnis, Lisa F. Barcellos, Barbara Laraia, John Rose, Shelly Roalstad, Timothy Simmons, T. J. Charles, Emmanuelle Waubant,

Nigella sativa pharmacological applications

Background: High salt intake may be associated with pro-inflammatory changes in the immune response, and increased clinical and MRI activity in adults with relapsing-remitting multiple sclerosis. Objective: We sought to determine if dietary salt intake is associated with pediatric-onset MS risk in a multicenter, case-control study. Methods: Pediatric-onset CIS/MS cases within four years of onset and controls less than 22 years old recruited from 14 pediatric-MS centers were studied. Dietary sodium intake was assessed using the validated Block Kids Food Screener (NutritionQuest). Sodium intake, excess sodium, and sodium terciles were compared between cases and controls. Logistic regression models were adjusted for age, gender, ethnicity, body mass index, and socioeconomic status. Results: Among 170 cases (mean age¼15.273.5) and 331 controls (mean age¼14.073.7), no significant difference in unadjusted mean sodium intake was found between cases (2044 mg/d) and controls (2030 mg/d, p ¼0.99). The proportion of subjects consuming excess sodium, based on the adequate intake for age and gender, was similar between cases and controls (65% versus 69%, p ¼0.34). There were no increased odds of higher sodium intake among cases as compared to controls (for each 100 mg/d increase in sodium, OR¼1.00, 95% CI 0.98, 1.02; p ¼0.93, for excess sodium intake, OR¼1.05, 95% CI 0.67, 1.64; p ¼0.84).